Spero Therapeutics Price To Earning vs. Net Income
| SPRO Stock | USD 2.30 0.10 4.17% |
For Spero Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spero Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spero Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spero Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spero Therapeutics over time as well as its relative position and ranking within its peers.
Spero Therapeutics' Revenue Breakdown by Earning Segment
Check out World Market Map.
Spero Therapeutics Revenue Breakdown by Earning Segment
By analyzing Spero Therapeutics' earnings estimates, investors can diagnose different trends across Spero Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spero Therapeutics Net Income vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spero Therapeutics's current stock value. Our valuation model uses many indicators to compare Spero Therapeutics value to that of its competitors to determine the firm's financial worth. Spero Therapeutics is currently regarded as top stock in price to earning category among its peers. It is rated below average in net income category among its peers . Spero Therapeutics reported last year Net Loss of (61.71 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spero Therapeutics' earnings, one of the primary drivers of an investment's value.Spero Net Income vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Spero Therapeutics |
| = | 81.20 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Spero Therapeutics |
| = | (68.57 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Spero Net Income Comparison
Spero Therapeutics is currently under evaluation in net income category among its peers.
Spero Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spero Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spero Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Spero Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Spero Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2.3 K | -2.4 K | |
| Interest Income | 5.4 M | 5.7 M | |
| Operating Income | -66 M | -69.3 M | |
| Net Loss | -61.7 M | -64.8 M | |
| Income Before Tax | -61.7 M | -64.8 M | |
| Total Other Income Expense Net | 5.5 M | 5.8 M | |
| Net Loss | -41.8 M | -43.9 M | |
| Net Loss | -61.7 M | -64.8 M | |
| Income Tax Expense | 3 M | 3.1 M | |
| Net Interest Income | 5.4 M | 5.7 M | |
| Non Operating Income Net Other | 749.7 K | 1.2 M | |
| Change To Netincome | 18.1 M | 19 M | |
| Net Loss | (1.14) | (1.20) | |
| Income Quality | 0.39 | 0.57 | |
| Net Income Per E B T | 0.81 | 0.66 |
Spero Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spero Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spero Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spero Therapeutics' important profitability drivers and their relationship over time.
Spero Therapeutics Earnings Estimation Breakdown
The calculation of Spero Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Spero Therapeutics is estimated to be -0.025 with the future projection ranging from a low of -0.025 to a high of -0.025. Please be aware that this consensus of annual earnings estimates for Spero Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.03 Lowest | Expected EPS | -0.03 Highest |
Spero Therapeutics Earnings Projection Consensus
Suppose the current estimates of Spero Therapeutics' value are higher than the current market price of the Spero Therapeutics stock. In this case, investors may conclude that Spero Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Spero Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 1 | 16.61% | -0.13 | -0.025 | -0.79 |
Spero Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Spero Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Spero Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Spero Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Spero Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Spero Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Spero Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Spero Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Spero Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-17 | 2025-09-30 | -0.39 | -0.13 | 0.26 | 66 | ||
2025-08-12 | 2025-06-30 | -0.57 | -0.03 | 0.54 | 94 | ||
2025-05-13 | 2025-03-31 | -0.55 | -0.2472 | 0.3028 | 55 | ||
2025-03-11 | 2024-12-31 | -0.31 | -0.3669 | -0.0569 | 18 | ||
2024-11-11 | 2024-09-30 | -0.5 | -0.32 | 0.18 | 36 | ||
2024-08-05 | 2024-06-30 | -0.38 | -0.33 | 0.05 | 13 | ||
2024-05-15 | 2024-03-31 | -0.04 | -0.24 | -0.2 | 500 | ||
2024-03-13 | 2023-12-31 | -0.1 | 0.96 | 1.06 | 1060 | ||
2023-11-13 | 2023-09-30 | -0.03 | 0.04 | 0.07 | 233 | ||
2023-08-10 | 2023-06-30 | -0.34 | -0.23 | 0.11 | 32 | ||
2023-05-11 | 2023-03-31 | -0.33 | -0.25 | 0.08 | 24 | ||
2023-03-30 | 2022-12-31 | 0.04 | 0.55 | 0.51 | 1275 | ||
2022-11-14 | 2022-09-30 | -0.3 | -0.33 | -0.03 | 10 | ||
2022-08-10 | 2022-06-30 | -0.93 | -0.87 | 0.06 | 6 | ||
2022-05-16 | 2022-03-31 | -0.87 | -1.01 | -0.14 | 16 | ||
2022-03-31 | 2021-12-31 | -0.75 | -0.9 | -0.15 | 20 | ||
2021-11-10 | 2021-09-30 | -0.66 | -0.7 | -0.04 | 6 | ||
2021-08-05 | 2021-06-30 | -0.75 | -0.63 | 0.12 | 16 | ||
2021-05-06 | 2021-03-31 | -0.64 | -0.66 | -0.02 | 3 | ||
2021-03-11 | 2020-12-31 | -0.74 | -0.68 | 0.06 | 8 | ||
2020-11-05 | 2020-09-30 | -0.87 | -0.86 | 0.01 | 1 | ||
2020-08-06 | 2020-06-30 | -1.12 | -0.85 | 0.27 | 24 | ||
2020-05-08 | 2020-03-31 | -1.25 | -1.19 | 0.06 | 4 | ||
2020-03-16 | 2019-12-31 | -1.08 | -1.32 | -0.24 | 22 | ||
2019-11-04 | 2019-09-30 | -0.85 | -0.95 | -0.1 | 11 | ||
2019-08-08 | 2019-06-30 | -0.65 | -0.74 | -0.09 | 13 | ||
2019-05-09 | 2019-03-31 | -0.78 | -0.29 | 0.49 | 62 | ||
2019-03-14 | 2018-12-31 | -0.75 | -0.6 | 0.15 | 20 | ||
2018-11-08 | 2018-09-30 | -0.63 | -0.6 | 0.03 | 4 | ||
2018-08-09 | 2018-06-30 | -0.77 | -0.69 | 0.08 | 10 | ||
2018-05-10 | 2018-03-31 | -1.2 | -0.74 | 0.46 | 38 | ||
2017-12-14 | 2017-09-30 | -2.43 | -36.02 | -33.59 | 1382 | ||
2017-08-30 | 2017-06-30 | 0 | -2.96 | -2.96 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -0.51 | -0.51 | 0 |
Use Spero Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Spero Therapeutics Pair Trading
Spero Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Spero Therapeutics position
In addition to having Spero Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Books Thematic Idea Now
Books
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
To fully project Spero Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spero Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spero Therapeutics' income statement, its balance sheet, and the statement of cash flows.